Transfusion-dependant, low-risk MDS: what are the options?

(5:56)

NTDT, or Non-transfusion Dependant Thalassemia - Ali Taher, MD, FRCP

(6:33)

The challenges associated with treating patients with non-transfusion-dependent thalassemia

(1:14)

New therapies for transfusion dependent MDS patients

(5:28)

Monitoring Iron Levels in Transfusion-Dependent MDS

(5:24)

Anemia and transfusion dependence on QoL in MDS

(1:31)

Treating transfusion dependent and independent beta-thalassemia, and BELIEVE/BEYOND trial updates

(8:38)

Quality of Life in Transfusion-Dependent MDS

(4:4)

What can clinicians do to address the impact of transfusion-dependent thalassemia on patients' QoL?

(2:40)

Embracing Life With Transfusion-Dependent Beta Thalassemia | Vertex Pharmaceuticals

(1:59)

Non-Transfusion Dependent Thalassemias: An Enduring Challenge

(1:2:9)

Novel approaches for transfusion dependent MDS

(4:11)

Beti-cel gene therapy for transfusion-dependent β-thalassemia: 7-year follow up data

(5:49)

Monitoring for Iron Overload in Transfusion-Dependent MDS

(6:34)

The impact of anemia and transfusion dependence on patient QoL in myelofibrosis

(1:30)

Toxicity of beti-cel in transfusion-dependent β-thalassemia

(1:48)

Parameters for Blood Transfusion in MDS

(4:7)

Past, present, and future management strategies for non-transfusion dependent β-thalassemia

(2:9)

Imetelstat for transfusion-dependent R/R MDS

(2:19)